The critical nature of lipid scavenging is further supported by the modest clinical efficacy of FASN inhibitors as a monotherapies for cancer treatment, as lipid-rich microenvironments in vivo may enable efficient lipid scavenging that diminishes the importance of de novo lipid synthesis (Wang et al. 2022; Lien et al. 2021; Medes, Thomas, and Weinhouse 1953). Here, FASN is linked to cancer.